Navigation Links
Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:8/16/2010

RYE, N.Y., Aug. 16 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference, scheduled for September 12-15 at the New York Palace Hotel in New York City.

Dr. Joan Fallon, Curemark's founder and CEO, will update investors on the progress of the company's clinical research for CM-AT, its autism treatment in development.  She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the FDA for CM – 4612 to treat attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial for the use of CM – 4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

"We are very happy to have this opportunity to present at the Rodman & Renshaw annual investment conference.  Curemark has achieved a variety of major milestones that we are looking forward to sharing with attendees," Fallon said.  

CM-AT, Curemark's autism treatment, addresses enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function.  Phase III clinical trials are underway at 13 sites nationwide for CM-AT, which has received Fast Track status from the FDA.  If approved, it will be one of the first therapies to address the underlying physiology of autism.          

Curemark's presentation is part of the 12th annual healthcare conference, an industry track that will be showcased during the Rodman & Renshaw Annual Global Investment Conference.  In addition to healthcare, the conference will highlight industry tracks including China, metals and mining, energy, technology, cleantech, community and regional banks, and REITs.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Opens Autism Trials at New Jersey Site
2. Curemark Begins Autism Trials at Two More Sites
3. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
4. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
5. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
9. Curemark Announces Senior Executive Promotions
10. Curemark CEO Presents at Epigenomics Conference
11. Curemark Closes Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... According to a new market report ... U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 ... was valued at US$ 5.89 Bn in 2014 and is ... to 2023 to reach US$ 7.99 Bn in 2023. ... needle free drug delivery devices and the market is estimated ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook ... Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the ... is their favorite way to cook a hot dog, far outpacing other cooking methods ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
Breaking Medicine News(10 mins):